| ZOMETA AND PAGET'S DISEASE |
| Paget's disease is a metabolic bone disease that involves bone destruction and regrowth which results in deformity. |
Current treatments are biphosphonates (etidronate
(Didronel), alendronate (Fosamax), pamidronate (Aredia),
tiludronate (Skelid), and risedronate (Actonel)) and calcitonin
(Miacalcin, Calcimar) and nonsteroidal anti-inflammatory
medications (NSAIDS; for pain).
Currently, Novartis' Zometa is under review by the U.S. FDA
as a treatment for Paget's disease. Zometa has been
approved for that use in some other countries. Zoledronic
acid is a bisphosponate administered as a single intravenous
infusion.
In two identical, randomized, double-blind, actively controlled
studies of 6 months' duration, researchers compared one
15-minute infusion of 5 mg of zoledronic acid with 60 days of
oral risedronate (30 mg per day). Researchers found that
96% of patients receiving zoledronic acid had a therapeutic
response, as compared with 74.3 percent of patients
receiving risedronate. And, alkaline phosphatase levels
normalized in 88.6 percent of patients in the zoledronic acid
group and 57.9 percent of patients in the risedronate group.
Reference:
Ian R. Reid. Comparison of a Single Infusion of Zoledronic Acid with
Risedronate for Paget's Disease. The New England Journal of
Medicine Volume 353:898-908 September 1, 2005 Number 9
Novartis drug aids bones in Paget's disease-study, Reuters, Aug 31,
2005.
Zoledronic Acid Improves Femoral Head Sphericity in a Rat Model of
Perthes Disease. RedNova online publication, August 7, 2005.
(Didronel), alendronate (Fosamax), pamidronate (Aredia),
tiludronate (Skelid), and risedronate (Actonel)) and calcitonin
(Miacalcin, Calcimar) and nonsteroidal anti-inflammatory
medications (NSAIDS; for pain).
Currently, Novartis' Zometa is under review by the U.S. FDA
as a treatment for Paget's disease. Zometa has been
approved for that use in some other countries. Zoledronic
acid is a bisphosponate administered as a single intravenous
infusion.
In two identical, randomized, double-blind, actively controlled
studies of 6 months' duration, researchers compared one
15-minute infusion of 5 mg of zoledronic acid with 60 days of
oral risedronate (30 mg per day). Researchers found that
96% of patients receiving zoledronic acid had a therapeutic
response, as compared with 74.3 percent of patients
receiving risedronate. And, alkaline phosphatase levels
normalized in 88.6 percent of patients in the zoledronic acid
group and 57.9 percent of patients in the risedronate group.
Reference:
Ian R. Reid. Comparison of a Single Infusion of Zoledronic Acid with
Risedronate for Paget's Disease. The New England Journal of
Medicine Volume 353:898-908 September 1, 2005 Number 9
Novartis drug aids bones in Paget's disease-study, Reuters, Aug 31,
2005.
Zoledronic Acid Improves Femoral Head Sphericity in a Rat Model of
Perthes Disease. RedNova online publication, August 7, 2005.
 |  |  |  |
THIS WEBSITE TALKS ABOUT THE SIDE EFFECTS AND THE POTENTIAL HEALTH BENEFITS OF HERBS, SUPPLEMENTS,
PHYTONUTRIENTS AND DRUG PRODUCTS. THIS WEBSITE ALSO TALKS ABOUT SOME POPULAR HEALTH ISSUES AND DISEASES.
ARTICLES IN THIS WEB SITE IS FOR YOUR REFERENCE ONLY. IF YOU HAVE ANY QUESTION, YOU SHOULD CONSULT WITH YOUR
DOCTOR IMMEDIATELY. ALL RIGHTS RESERVED 2008. DO NOT COPY NOR TRANSFER ARTICLES TO OTHER WEBSITES NOR OTHER
FORMS OF PUBLICATIONS. Privacy Policy. ARTICLE INDEX
PHYTONUTRIENTS AND DRUG PRODUCTS. THIS WEBSITE ALSO TALKS ABOUT SOME POPULAR HEALTH ISSUES AND DISEASES.
ARTICLES IN THIS WEB SITE IS FOR YOUR REFERENCE ONLY. IF YOU HAVE ANY QUESTION, YOU SHOULD CONSULT WITH YOUR
DOCTOR IMMEDIATELY. ALL RIGHTS RESERVED 2008. DO NOT COPY NOR TRANSFER ARTICLES TO OTHER WEBSITES NOR OTHER
FORMS OF PUBLICATIONS. Privacy Policy. ARTICLE INDEX
 | |  | |  | |  | |  | |  | |  |